| Size | Price | |
|---|---|---|
| Other Sizes |
| ln Vitro |
utilizing plastic film to make absorbent
|
|---|---|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Cyanuric acid, when given to rats, was rapidly excreted in an unchanged form. Metabolism / Metabolites (14)C-Labeled cyanuric acid...liberated 13.2 & 7.9% of absorbed radioactivity as (14)CO2 from corn & alfalfa, respectively /after an uptake period lasting from 4 days to 2 wk followed by a depletion period of up to 6 wk. The mechanism involved is triazine ring cleavage./ Approx 90% of the administered dose is reported to be excreted in urine within 12 hr and 99% of this is identified as cyanuric acid. Biological Half-Life 90% excreted within 12 hours, and of this 99% is excreted unchanged as cyanuric acid; [HSDB] |
| Toxicity/Toxicokinetics |
Toxicity Data
LC50 (rat) > 612 mg/m3 Interactions The major pet food recall associated with acute renal failure in dogs and cats focused initially on melamine as the suspect toxicant. In the course of the investigation, cyanuric acid was identified in addition to melamine in the offending food. The purpose of this study was to characterize the toxicity potential of melamine, cyanuric acid, and a combination of melamine and cyanuric acid in cats. In this pilot study, melamine was added to the diet of 2 cats at 0.5% and 1%, respectively. Cyanuric acid was added to the diet of 1 cat at increasing doses of 0.2%, 0.5%, and 1% over the course of 10 days. Melamine and cyanuric acid were administered together at 0%, 0.2%, 0.5%, and 1% to 1 cat per dose group. No effect on renal function was observed in cats fed with melamine or cyanuric acid alone. Cats dosed with a combination were euthanized at 48 hours after dosing because of acute renal failure. Urine and touch impressions of kidneys from all cats dosed with the combination revealed the presence of fan-shaped, birefringent crystals. Histopathologic findings were limited to the kidneys and included crystals primarily within tubules of the distal nephron, severe renal interstitial edema, and hemorrhage at the corticomedullary junction. The kidneys contained estimated melamine concentrations of 496 to 734 mg/kg wet weight and estimated cyanuric acid concentrations of 487 to 690 mg/kg wet weight. The results demonstrate that the combination of melamine and cyanuric acid is responsible for acute renal failure in cats. Non-Human Toxicity Values LD50 Rat, Sprague-Dawley (male & female) oral >5000 mg/kg bw LD50 Rabbit, New Zealand White (male & female) dermal >5000 mg/kg bw LD50 Rat oral 7700 mg/kg bw. LD50 Cat iv 2144 mg/kg bw. /Sodium isocyanurate/ For more Non-Human Toxicity Values (Complete) data for CYANURIC ACID (9 total), please visit the HSDB record page. |
| Additional Infomation |
Crystals. (NTP, 1992)
Cyanuric acid is the enol tautomer of isocyanuric acid. It has a role as a xenobiotic. It is a member of 1,3,5-triazines and a heteroaryl hydroxy compound. It is a tautomer of an isocyanuric acid. Cyanuric acid has been reported in Acokanthera oblongifolia with data available. |
| Molecular Formula |
C3H3N3O3
|
|---|---|
| Molecular Weight |
129.07
|
| Exact Mass |
129.017
|
| CAS # |
108-80-5
|
| Related CAS # |
Cyanuric acid-13C3;201996-37-4;Cyanuric acid-13C3,15N3
|
| PubChem CID |
7956
|
| Appearance |
White to off-white solid powder
|
| Density |
2.0±0.1 g/cm3
|
| Boiling Point |
793.4±43.0 °C at 760 mmHg
|
| Melting Point |
360 °C
|
| Flash Point |
433.6±28.2 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.748
|
| LogP |
-1.41
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
9
|
| Complexity |
136
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ZFSLODLOARCGLH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C3H3N3O3/c7-1-4-2(8)6-3(9)5-1/h(H3,4,5,6,7,8,9)
|
| Chemical Name |
1,3,5-triazinane-2,4,6-trione
|
| Synonyms |
Cyanuric acid Isocyanuric acid Isocyanurate acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.7477 mL | 38.7387 mL | 77.4773 mL | |
| 5 mM | 1.5495 mL | 7.7477 mL | 15.4955 mL | |
| 10 mM | 0.7748 mL | 3.8739 mL | 7.7477 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
